PE20190732A1 - Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje - Google Patents
Compuestos y composiciones como inhibidores de los receptores endosomales tipo peajeInfo
- Publication number
- PE20190732A1 PE20190732A1 PE2019000478A PE2019000478A PE20190732A1 PE 20190732 A1 PE20190732 A1 PE 20190732A1 PE 2019000478 A PE2019000478 A PE 2019000478A PE 2019000478 A PE2019000478 A PE 2019000478A PE 20190732 A1 PE20190732 A1 PE 20190732A1
- Authority
- PE
- Peru
- Prior art keywords
- type
- methyl
- pyrazolo
- pyridin
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Se refiere a un compuesto que tiene la estructura de la Formula (A), o una sal farmaceuticamente aceptable del mismo; en donde L es -CH2- o -CH2CH2-; Y1 es -CH2- o -CH2CH2-; Y2 es -CH2- o -CH2CH2-; Y3 es -CH2-, -XCH2- o -CH2X-; X es -CH2- u O; R1 es -NHC(=O)R6, entre otros; R2 es H, alquiloC1-C6, haloalquilo C1-C6 o alquilo C1-C6; R6 es un cicloalquilo C3-C6, un oxa-3-azabiciclo[3.2.1] octano o una heterocicloalquilo de 4-6 miembrosque tiene 1 a 2 miembros de anillo, R17 puede ser H y alquilo C1-C6. Son compuestos preferidos 4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3- c]piridin-1-il)metil)biciclo[2,2,2]octan-1-amina; 4-((3-metil-5-(6-metil-1H-pirazolo[3,4-b]piridin-4-il)-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciclo[2,2,2]octan-1-amina. Dichos compuestos son capaces de inhibir un receptor endosomal tipo Peaje (por ejemplo, TLR7, TLR8 o TLR9) y cualquier combinacion de los mismos y son utiles en el tratamiento de enfermedades autoinmunes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385726P | 2016-09-09 | 2016-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190732A1 true PE20190732A1 (es) | 2019-05-23 |
Family
ID=60001955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000478A PE20190732A1 (es) | 2016-09-09 | 2017-09-06 | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US10954233B2 (es) |
| EP (2) | EP4059934A1 (es) |
| JP (1) | JP6779371B2 (es) |
| KR (2) | KR20190039809A (es) |
| CN (2) | CN109641899B (es) |
| AU (1) | AU2017323584C1 (es) |
| BR (1) | BR112019004597A2 (es) |
| CA (1) | CA3031585A1 (es) |
| CL (1) | CL2019000588A1 (es) |
| CO (1) | CO2019003397A2 (es) |
| CR (1) | CR20190119A (es) |
| CU (1) | CU24526B1 (es) |
| CY (1) | CY1125007T1 (es) |
| DK (1) | DK3510033T3 (es) |
| DO (1) | DOP2019000055A (es) |
| EA (1) | EA036880B1 (es) |
| EC (1) | ECSP19024046A (es) |
| ES (1) | ES2905981T3 (es) |
| HR (1) | HRP20220144T1 (es) |
| HU (1) | HUE057254T2 (es) |
| IL (1) | IL265159B (es) |
| JO (1) | JOP20190041B1 (es) |
| LT (1) | LT3510033T (es) |
| MA (1) | MA46196A (es) |
| MX (1) | MX2019002797A (es) |
| MY (1) | MY194813A (es) |
| PE (1) | PE20190732A1 (es) |
| PH (1) | PH12019500161A1 (es) |
| PL (1) | PL3510033T3 (es) |
| PT (1) | PT3510033T (es) |
| RS (1) | RS62913B1 (es) |
| RU (1) | RU2759678C2 (es) |
| SG (1) | SG11201900482SA (es) |
| SI (1) | SI3510033T1 (es) |
| WO (1) | WO2018047081A1 (es) |
| ZA (1) | ZA201900227B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3929196T3 (pl) | 2013-09-24 | 2023-12-11 | Fujifilm Corporation | Kompozycja farmaceutyczna związku zawierającego atom azotu lub jego soli, lub ich kompleksu z metalem |
| CN115317603A (zh) | 2016-07-07 | 2022-11-11 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| BR112019004597A2 (pt) | 2016-09-09 | 2019-06-11 | Novartis Ag | compostos e composições como inibidores de receptores endossomais do tipo toll |
| IL265921B1 (en) | 2016-10-14 | 2024-01-01 | Prec Biosciences Inc | Transgenic meganonucleases specific for recognition sequences in the hepatitis B virus genome |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| WO2019123294A2 (en) | 2017-12-22 | 2019-06-27 | Novartis Ag | Novel uses of pyrazolo piperidine derivatives |
| WO2019155042A1 (en) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| WO2019193543A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| WO2019220390A1 (en) * | 2018-05-18 | 2019-11-21 | Novartis Ag | Crystalline forms of a tlr7/tlr8 inhibitor |
| WO2019238616A1 (en) | 2018-06-12 | 2019-12-19 | F. Hoffmann-La Roche Ag | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| CN112584903A (zh) | 2018-07-23 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 用于自身免疫性疾病治疗的新型哌嗪化合物 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN112638908A (zh) | 2018-09-04 | 2021-04-09 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的苯并噻唑类化合物 |
| JP2022502353A (ja) | 2018-09-06 | 2022-01-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の処置のための新規の環状アミジン化合物 |
| JP2022501326A (ja) * | 2018-09-07 | 2022-01-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の治療のための新規ピロリジンアミン化合物 |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ３’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CN113543851A (zh) | 2019-03-07 | 2021-10-22 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| WO2020240272A1 (en) * | 2019-05-31 | 2020-12-03 | Dr.Reddy's Institute Of Life Sciences | Preparation of novel 1 h-pyrazolo[4,3-d]pyrimidines, their compositions, synthesis and methods of using them for treating tuberculosis |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN114555799A (zh) | 2019-09-30 | 2022-05-27 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| EP4069729A1 (en) | 2019-12-06 | 2022-10-12 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2022013136A1 (en) | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
| US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022351495A1 (en) | 2021-09-24 | 2024-02-01 | F. Hoffmann-La Roche Ag | Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease |
| TW202337443A (zh) | 2022-01-11 | 2023-10-01 | 瑞士商諾華公司 | 使用ｔｌｒ７／８拮抗劑治療ｓｊｏｇｒｅｎ氏症候群或混合性結締組織病之方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2416527C (en) | 2000-08-10 | 2009-12-22 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| WO2004080457A1 (en) | 2003-03-11 | 2004-09-23 | Pharmacia Italia S.P.A. | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US20060089378A1 (en) | 2004-10-27 | 2006-04-27 | Mingde Xia | Tetrahydro-pyridinyl pyrazole cannabinoid modulators |
| WO2007022280A1 (en) * | 2005-08-16 | 2007-02-22 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| WO2007034817A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| US20070254913A1 (en) | 2006-04-19 | 2007-11-01 | Dunn Robert F | Phosphodiesterase 4 inhibitors |
| US8093257B2 (en) | 2007-05-04 | 2012-01-10 | Bristol-Myers Squibb Company | [6,5]-bicyclic GPR119 G protein-coupled receptor agonists |
| CA2704266A1 (en) * | 2007-11-02 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
| CN105669552A (zh) | 2009-08-18 | 2016-06-15 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
| NZ598933A (en) * | 2009-10-22 | 2013-04-26 | Gilead Sciences Inc | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
| WO2012154608A1 (en) | 2011-05-06 | 2012-11-15 | Intellikine, Llc | Reactive mtor and pi3 kinase inhibitors and uses thereof |
| AU2012275499A1 (en) | 2011-06-27 | 2013-12-19 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
| ES2716811T3 (es) * | 2012-02-08 | 2019-06-17 | Janssen Sciences Ireland Unlimited Co | Derivados piperidinopirimidínicos para el tratamiento de infecciones víricas |
| JO3407B1 (ar) * | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| WO2014034719A1 (ja) | 2012-08-29 | 2014-03-06 | 興和株式会社 | Ｔｌｒ阻害作用を有するキノリン誘導体 |
| HUE037064T2 (hu) | 2012-10-10 | 2018-08-28 | Janssen Sciences Ireland Uc | Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére |
| BR112015016395A2 (pt) | 2013-01-18 | 2017-07-11 | Hoffmann La Roche | pirazóis 3-substituídos e uso como inibidores de dlk |
| WO2014159802A1 (en) | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Bicyclo [2.2.2] acid gpr120 modulators |
| ES2637816T3 (es) | 2013-05-02 | 2017-10-17 | Pfizer Inc. | Derivados de imidazo-triazina como inhibidores de PDE10 |
| US10471139B2 (en) | 2013-08-15 | 2019-11-12 | The University Of Kansas | Toll-like receptor agonists |
| WO2015024011A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | Antibacterial compounds |
| SG11201601199QA (en) | 2013-08-19 | 2016-03-30 | Univ Kingston | Carbene-functionalized composite materials |
| JP2016533385A (ja) | 2013-08-22 | 2016-10-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アルキニルアルコール及び使用方法 |
| WO2015036044A1 (en) | 2013-09-13 | 2015-03-19 | Telormedix Sa | Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood |
| WO2015057659A1 (en) * | 2013-10-14 | 2015-04-23 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| EP3057948B1 (en) | 2013-10-14 | 2018-03-14 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline derivatives |
| TW201613919A (en) * | 2014-07-02 | 2016-04-16 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| UA117634C2 (uk) | 2014-08-15 | 2018-08-27 | Чиа Тай Тяньцін Фармасьютикал Ґруп Ко., Лтд. | Піролопіримідинові сполуки, що використовуються як агоніст tlr7 |
| ES2746839T3 (es) * | 2014-12-18 | 2020-03-09 | Pfizer | Derivados de pirimidina y triazina y su uso como inhibidores de AXL |
| US9550779B2 (en) | 2014-12-30 | 2017-01-24 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis B infections |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| US10308628B2 (en) | 2015-03-12 | 2019-06-04 | Novartis Ag | Heterocyclic compounds and methods for their use |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| BR112019004597A2 (pt) | 2016-09-09 | 2019-06-11 | Novartis Ag | compostos e composições como inibidores de receptores endossomais do tipo toll |
-
2017
- 2017-09-06 BR BR112019004597A patent/BR112019004597A2/pt active Search and Examination
- 2017-09-06 MX MX2019002797A patent/MX2019002797A/es unknown
- 2017-09-06 DK DK17777966.7T patent/DK3510033T3/da active
- 2017-09-06 MA MA046196A patent/MA46196A/fr unknown
- 2017-09-06 CN CN201780053304.6A patent/CN109641899B/zh active Active
- 2017-09-06 CN CN202210863391.4A patent/CN115215886A/zh active Pending
- 2017-09-06 EP EP21208454.5A patent/EP4059934A1/en active Pending
- 2017-09-06 CU CU2019000018A patent/CU24526B1/es unknown
- 2017-09-06 PE PE2019000478A patent/PE20190732A1/es unknown
- 2017-09-06 ES ES17777966T patent/ES2905981T3/es active Active
- 2017-09-06 KR KR1020197008484A patent/KR20190039809A/ko not_active IP Right Cessation
- 2017-09-06 MY MYPI2019000071A patent/MY194813A/en unknown
- 2017-09-06 SG SG11201900482SA patent/SG11201900482SA/en unknown
- 2017-09-06 PT PT177779667T patent/PT3510033T/pt unknown
- 2017-09-06 LT LTEPPCT/IB2017/055375T patent/LT3510033T/lt unknown
- 2017-09-06 RU RU2019110157A patent/RU2759678C2/ru active
- 2017-09-06 AU AU2017323584A patent/AU2017323584C1/en active Active
- 2017-09-06 CR CR20190119A patent/CR20190119A/es unknown
- 2017-09-06 HR HRP20220144TT patent/HRP20220144T1/hr unknown
- 2017-09-06 JP JP2019513008A patent/JP6779371B2/ja active Active
- 2017-09-06 EP EP17777966.7A patent/EP3510033B1/en active Active
- 2017-09-06 RS RS20220087A patent/RS62913B1/sr unknown
- 2017-09-06 HU HUE17777966A patent/HUE057254T2/hu unknown
- 2017-09-06 CA CA3031585A patent/CA3031585A1/en active Pending
- 2017-09-06 US US16/330,820 patent/US10954233B2/en active Active
- 2017-09-06 PL PL17777966T patent/PL3510033T3/pl unknown
- 2017-09-06 KR KR1020217018684A patent/KR102411532B1/ko active IP Right Grant
- 2017-09-06 JO JOP/2019/0041A patent/JOP20190041B1/ar active
- 2017-09-06 WO PCT/IB2017/055375 patent/WO2018047081A1/en unknown
- 2017-09-06 SI SI201731065T patent/SI3510033T1/sl unknown
- 2017-09-06 EA EA201990657A patent/EA036880B1/ru not_active IP Right Cessation
-
2019
- 2019-01-14 ZA ZA201900227A patent/ZA201900227B/en unknown
- 2019-01-22 PH PH12019500161A patent/PH12019500161A1/en unknown
- 2019-03-04 IL IL265159A patent/IL265159B/en unknown
- 2019-03-06 DO DO2019000055A patent/DOP2019000055A/es unknown
- 2019-03-08 CL CL2019000588A patent/CL2019000588A1/es unknown
- 2019-04-05 CO CONC2019/0003397A patent/CO2019003397A2/es unknown
- 2019-04-05 EC ECSENADI201924046A patent/ECSP19024046A/es unknown
-
2020
- 2020-12-16 US US17/124,346 patent/US20210101902A1/en active Pending
-
2022
- 2022-02-22 CY CY20221100153T patent/CY1125007T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190732A1 (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje | |
| PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR127309A2 (es) | Derivados de piridazinona | |
| PE20221905A1 (es) | Aminas biciclicas como inhibidoras de la cdk2 | |
| CO6241157A2 (es) | "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9" | |
| MX2020005873A (es) | Compuestos de 6-azaindol. | |
| AR102213A1 (es) | Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| UY35935A (es) | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 | |
| AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
| AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR063318A1 (es) | Pirazoliltienopiridinas terapeuticas | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR087841A1 (es) | Derivados de tetrahidrotriazolopirimidina | |
| AR078535A1 (es) | Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras | |
| AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico | |
| RS54833B1 (sr) | Novi hiralni n-acil-5,6,7, (8-supstituisan)-tetrahidro-[1,2,4]triazolo [4,3-a]pirazini kao selektivni antagonisti nk-3 receptora, farmaceutsko jedinjenje, i postupci za upotrebu u nk-3 receptorom posredovanim poremećajima | |
| AR094550A1 (es) | Inhibidores de btk | |
| AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa |